Literature DB >> 2001928

Human crystalline lens phospholipid analysis with age.

T E Merchant1, J H Lass, P Meneses, J V Greiner, T Glonek.   

Abstract

Paired human crystalline lenses (n = 21, patient ages 20-79 years) were extracted for lipids with chloroform-methanol 2:1, using the Folch method. The extracted crude lipids were analyzed at 202.4 MHz by phosphorus-31 magnetic resonance spectroscopy (31P NMR). Fourteen membrane phospholipids were detected including phosphatidylcholine (PC), lysophosphatidylcholine (LPC), phosphatidylcholine plasmalogen (PC plas), phosphatidylethanolamine (PE), phosphatidylethanolamine plasmalogen, lysophosphatidylethanolamine (PA), phosphatidylglycerol (PG), lysophosphatidylglycerol, phosphatidylserine (PS), phosphatidic acid, phosphatidylinositol, sphingomyelin (SPH), and two uncharacterized phospholipids. The uncharacterized phospholipid at 0.13 was the predominant phospholipid, comprising 43.20% of the lens phospholipid profile. A decrease in mole percent of phosphorus concentrations of PE, PC plas, and PC and an increase in SPH correlated with age. The following computed indices decreased with age: PC/PG and PE/PS; PC + PE; (PC + PC plas); and PC/PS. The following computed indices increased with age: (PC + SPH)/(PE + PS), SPH/PG, (PC + SPH)/(PE + PS), LPC/PC, LPE/PE, SPH/PE, and SPH/PC. Changes in membrane phospholipids of the crystalline lens with age as detected by 31P NMR can be used to fingerprint lens maturation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001928

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Changes in human meibum lipid composition with age using nuclear magnetic resonance spectroscopy.

Authors:  Douglas Borchman; Gary N Foulks; Marta C Yappert; Sarah E Milliner
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-31       Impact factor: 4.799

2.  The neuropathy of elderly mice.

Authors:  A Robertson; B Day; M Pollock; P Collier
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

3.  Sphingolipid distribution changes with age in the human lens.

Authors:  Jane M Deeley; Joseph A Hankin; Michael G Friedrich; Robert C Murphy; Roger J W Truscott; Todd W Mitchell; Stephen J Blanksby
Journal:  J Lipid Res       Date:  2010-06-14       Impact factor: 5.922

4.  Differences in human meibum lipid composition with meibomian gland dysfunction using NMR and principal component analysis.

Authors:  Douglas Borchman; Gary N Foulks; Marta C Yappert; Sarah E Milliner
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

5.  alpha-Crystallin chaperone-like activity and membrane binding in age-related cataracts.

Authors:  Brian A Cobb; J Mark Petrash
Journal:  Biochemistry       Date:  2002-01-15       Impact factor: 3.162

6.  Factors influencing alpha-crystallin association with phospholipid vesicles.

Authors:  Brian A Cobb; J Mark Petrash
Journal:  Mol Vis       Date:  2002-03-22       Impact factor: 2.367

7.  Analysis of the composition of lipid in human meibum from normal infants, children, adolescents, adults, and adults with meibomian gland dysfunction using ¹H-NMR spectroscopy.

Authors:  Rashmi K Shrestha; Douglas Borchman; Gary N Foulks; Marta C Yappert; Sarah E Milliner
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-21       Impact factor: 4.799

Review 8.  Lipids and the ocular lens.

Authors:  Douglas Borchman; Marta C Yappert
Journal:  J Lipid Res       Date:  2010-04-20       Impact factor: 5.922

9.  31P NMR quantification and monophasic solvent purification of human and bovine lens phospholipids.

Authors:  William C Byrdwell; Hidetoshi Sato; Arne K Schwarz; Douglas Borchman; M C Yappert; Daxin Tang
Journal:  Lipids       Date:  2002-11       Impact factor: 1.880

10.  Meningioma phospholipid profiles measured by 31P nuclear magnetic resonance spectroscopy.

Authors:  L Seijo; T E Merchant; L T van der Ven; B D Minsky; T Glonek
Journal:  Lipids       Date:  1994-05       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.